(Q39291545)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

ChEBI release 2020-05-28

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Stefano Sacchi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Monica Civallero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Maria Cosenza

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Luigi Marcheselli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

25 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1597-1606

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Pathogenesis of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Novel targeted therapies for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

New molecular targets in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Present and future of PI3K pathway inhibition in cancer: perspectives and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Mantle cell lymphoma: advances in biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Targeting mTOR in mantle cell lymphoma: current and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Long-term culture of human bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Signal transduction inhibitor therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.719871

10.1517/13543784.2012.719871

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920938%20AND%20SRC:MED&resulttype=core&format=json

release_2slif3vn3ngalpopfodvkfjekm

12 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2slif3vn3ngalpopfodvkfjekm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference